Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Xtant Medical Holdings (XTNT) Short-Term Debt repayments (2017 - 2025)

Xtant Medical Holdings has reported Short-Term Debt repayments over the past 6 years, most recently at $26.5 million for Q3 2025.

  • Quarterly Short-Term Debt repayments rose 2.71% to $26.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $105.5 million through Sep 2025, up 5.16% year-over-year, with the annual reading at $105.1 million for FY2024, 36.59% up from the prior year.
  • Short-Term Debt repayments was $26.5 million for Q3 2025 at Xtant Medical Holdings, up from $25.9 million in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at $27.5 million in Q2 2024 and troughed at $12.3 million in Q1 2022.
  • The 5-year median for Short-Term Debt repayments is $20.1 million (2023), against an average of $20.1 million.
  • Year-over-year, Short-Term Debt repayments fell 6.36% in 2022 and then surged 55.04% in 2024.
  • A 5-year view of Short-Term Debt repayments shows it stood at $13.5 million in 2021, then rose by 10.6% to $14.9 million in 2022, then skyrocketed by 49.44% to $22.3 million in 2023, then rose by 21.75% to $27.1 million in 2024, then fell by 2.33% to $26.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Short-Term Debt repayments are $26.5 million (Q3 2025), $25.9 million (Q2 2025), and $26.0 million (Q1 2025).